Core Viewpoint - Gilead Sciences (GILD) is currently viewed as a more attractive undervalued stock option compared to Amgen (AMGN) based on various financial metrics and earnings outlook [1][7]. Valuation Metrics - GILD has a forward P/E ratio of 14.24, while AMGN's forward P/E is 15.10, indicating GILD may be undervalued relative to AMGN [5]. - The PEG ratio for GILD is 0.73, suggesting a favorable valuation when considering expected earnings growth, compared to AMGN's PEG ratio of 2.60 [5]. - GILD's P/B ratio stands at 7.26, significantly lower than AMGN's P/B ratio of 28.50, further supporting GILD's valuation as more attractive [6]. Earnings Outlook - GILD is experiencing an improving earnings outlook, which enhances its position in the Zacks Rank model, indicating a positive trend in earnings estimates [3][7].

Company Performance - Gilead Sciences (GILD) has returned 16.8% year-to-date, outperforming the average gain of 3.6% for Medical stocks [4] - The Zacks Consensus Estimate for GILD's full-year earnings has increased by 4.2% over the past quarter, indicating improved analyst sentiment and earnings outlook [3] - Gilead Sciences is part of the Medical - Biomedical and Genetics industry, which has gained an average of 4.3% this year, further highlighting GILD's strong performance [5] Industry Context - The Medical sector includes 1011 individual stocks and currently holds a Zacks Sector Rank of 5, reflecting the average performance of stocks within this sector [2] - The Medical - Instruments industry, which includes AngioDynamics (ANGO), has seen a decline of -2.1% since the beginning of the year, contrasting with Gilead's performance [6] - AngioDynamics has returned 11.1% year-to-date and has a consensus EPS estimate that increased by 9% over the past three months, also holding a Zacks Rank of 2 (Buy) [4][5]

Core Viewpoint - Gilead Sciences is experiencing a mixed performance in the stock market, with upcoming earnings expected to show significant growth in EPS while revenue remains relatively stable compared to the previous year [1][3][4]. Company Performance - Gilead Sciences closed at $106.67, reflecting a decrease of -0.38% from the previous day, underperforming against the S&P 500, which gained 1.77% [1] - Over the past month, Gilead's shares have declined by 2.61%, which is a smaller loss compared to the Medical sector's decline of 1.17% and the S&P 500's loss of 5.73% [2] Earnings Expectations - The company is anticipated to report an EPS of $1.73, representing a substantial increase of 231.06% from the same quarter last year [3] - Revenue is projected to be $6.78 billion, reflecting a modest increase of 1.36% year-over-year [3] - For the full year, analysts expect earnings of $7.87 per share and revenue of $28.55 billion, indicating a year-over-year earnings growth of 70.35% but a slight revenue decline of -0.7% [4] Analyst Estimates and Ratings - Recent changes in analyst estimates for Gilead Sciences are crucial as they indicate short-term business trends and analysts' confidence in the company's performance [5] - The Zacks Rank system currently rates Gilead Sciences as 2 (Buy), with a 0.05% increase in the Zacks Consensus EPS estimate over the past month [7] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 13.61, which is lower than the industry average of 18.52, suggesting that the stock is trading at a discount [8] - The company also has a PEG ratio of 0.7, compared to the industry average PEG ratio of 1.51, indicating favorable valuation relative to expected earnings growth [9] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead Sciences, holds a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [10]

Company Performance - Gilead Sciences (GILD) closed at $105.87, down 1.53% from the previous trading day, underperforming the S&P 500's loss of 0.22% [1] - Over the past month, Gilead's shares have decreased by 0.13%, which is better than the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48% [1] Earnings Forecast - Gilead is expected to report an EPS of $1.73, representing a significant growth of 231.06% compared to the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $6.78 billion, reflecting a 1.36% increase from the previous year [2] Annual Estimates - For the entire year, earnings are forecasted at $7.87 per share, indicating a growth of 70.35%, while revenue is expected to be $28.55 billion, showing a slight decline of 0.7% compared to the previous year [3] - Recent analyst estimate revisions suggest a positive outlook for Gilead's business and profitability [3] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 13.67, which is lower than the industry's average Forward P/E of 19.05 [6] - The company has a PEG ratio of 0.7, compared to the industry average PEG ratio of 1.56, indicating a favorable valuation relative to projected earnings growth [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 75, placing it in the top 30% of over 250 industries [7] - Research indicates that higher-ranked industries tend to outperform lower-ranked ones by a factor of 2 to 1 [7]

Core Viewpoint - Gilead Sciences, Inc. (GILD) faces potential challenges due to reported federal funding cuts for HIV prevention, impacting investor sentiment despite the company's strong market position in HIV treatments [1][2]. Company Overview - Gilead Sciences has a leading portfolio of HIV treatments, including two drugs for prevention: Descovy and Truvada [1]. - The company is seeking FDA approval for lenacapavir, which has shown promising efficacy in HIV prevention, particularly in cisgender women [5][6]. Market Position - Descovy holds over 40% market share in the U.S. PrEP market, indicating strong uptake among at-risk populations [4]. - GILD's shares have increased by 17.2% year-to-date, outperforming the industry growth of 6.8% [3]. Competitive Landscape - GSK, another player in the HIV market, has seen a 13% growth in HIV sales in 2024, driven by demand for long-acting injectable medicines [11]. - The FDA has approved Apretude, a long-acting injectable form of PrEP, which adds to the competitive pressure on Gilead's offerings [9][10]. Future Prospects - The approval of lenacapavir is anticipated to strengthen Gilead's HIV franchise, as it requires administration only twice a year, offering a competitive edge over daily oral medications [7]. - The FDA has granted Priority Review for lenacapavir, with a target action date set for June 19, 2025 [6].

Core Viewpoint - Gilead Sciences Inc (NASDAQ:GILD) has experienced a significant decline in stock price due to potential funding cuts for domestic HIV prevention programs by the Trump administration, impacting the company's core business in HIV and AIDS treatments [1][2]. Group 1: Stock Performance - GILD's stock is down 2.6% to $107.34, marking its lowest level since mid-February [1]. - The stock has pulled back from a nine-year high of $119.96 reached on March 10, now facing its seventh loss in eight sessions [2]. - Despite the recent decline, GILD remains up 46.2% year-over-year and 16.3% year-to-date [2]. Group 2: Options Activity - There has been a notable increase in put options activity, with 3,000 puts exchanged today, double the typical volume [2]. - The March 103 put option is the most popular, indicating bearish sentiment as new positions are being opened [2]. - GILD's 10-day put/call volume ratio of 0.95 ranks higher than 99% of readings from the past year, suggesting heightened bearish activity [3].

Core Viewpoint - Gilead Sciences, Inc. (GILD) has shown strong stock performance, hitting a 52-week high and outperforming its industry and the S&P 500, driven by positive data and pipeline advancements [1][3]. Group 1: Stock Performance - GILD's stock reached a 52-week high of $119.96 on March 10 and is currently trading at $111.44 [1]. - The stock has gained 5.5% in the past month, while the industry grew by only 1.2% [1]. Group 2: HIV Franchise - Gilead maintains a leading portfolio in HIV treatments, with over 50% market share in the U.S. as of Q4 [4]. - The flagship HIV therapy, Biktarvy, continues to drive sales growth [4]. - Descovy for PrEP has over 40% market share in the U.S. [5]. - The pipeline candidate lenacapavir shows 100% efficacy for HIV prevention in cisgender women, with potential for twice-yearly administration [5][6]. Group 3: New Drug Approvals - The FDA granted accelerated approval to seladelpar for primary biliary cholangitis (PBC), enhancing Gilead's liver disease portfolio [9][10]. - Gilead's acquisition of CymaBay Therapeutics for $4.3 billion adds seladelpar to its pipeline [10]. Group 4: Strategic Partnerships - Gilead formed a strategic partnership with LEO Pharma to enhance its inflammation research portfolio [11]. - A collaboration with Terray Therapeutics aims to develop novel small-molecule therapies [11]. Group 5: Oncology Portfolio - The breast cancer drug Trodelvy has performed well, receiving Breakthrough Therapy Designation for small cell lung cancer [12]. - However, setbacks occurred with late-stage studies for Trodelvy in urothelial cancer and non-small cell lung cancer [13]. Group 6: Cell Therapy Challenges - Gilead's Cell Therapy franchise, including Yescarta and Tecartus, faces competitive pressures expected to continue into 2025 [14]. Group 7: Financial Outlook - GILD's shares trade at a price/earnings ratio of 14.01x forward earnings, lower than the industry average of 16.60x [15]. - Earnings estimates for 2025 and 2026 have increased, indicating positive revisions [16]. - The company has a strong cash position of $10 billion as of December 31, 2024, supporting a sustainable dividend yield of 2.84% [20].

Industry Overview - The Zacks Medical – Biomedical and Genetics industry group ranks in the top 26% out of over 250 industries, indicating strong performance and potential for continued outperformance over the next 3 to 6 months [7] - The industry group has favorable metrics, with a PEG ratio of 1.57 and projected EPS growth of 13.18%, compared to the iShares S&P 500's PEG ratio of 2.12 and projected EPS growth of 6.87% [9] Company Highlights - Gilead Sciences (GILD) is a leading stock in the biomedical sector, known for its innovative medicines for life-threatening illnesses. It has a Zacks Rank of 2 (Buy) and has a trailing four-quarter average earnings surprise of 19.5% [11][12] - GILD reported fourth-quarter earnings of $1.90 per share, exceeding consensus estimates by 13.8%. The stock is trading at 14.5 times forward earnings and has increased over 23% in 2025, reaching a 52-week high [12][13] - Jazz Pharmaceuticals (JAZZ) is another strong performer in the same industry, holding a Zacks Rank of 1 (Strong Buy). The company focuses on neuroscience and oncology and has surpassed earnings estimates in three of the past four quarters [15][16] - JAZZ reported fourth-quarter earnings of $6.60 per share, a 14% surprise over consensus estimates. The stock trades at six times forward earnings, significantly below the industry average, and has advanced more than 11% this year [16][17][18] Investment Strategy - The Zacks Rank methodology helps identify stocks with positive earnings estimate revisions, which can lead to better investment outcomes. Stocks with a Zacks Rank of 3 or better and a positive Earnings ESP have produced positive surprises 70% of the time [20] - JAZZ has a Zacks Rank of 1 and an Earnings ESP of +3.6%, indicating potential for another earnings beat in the upcoming Q1 results [21]

Core Insights - Investors in the Medical - Biomedical and Genetics sector should consider Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) for potential value opportunities [1] Valuation Metrics - GILD has a forward P/E ratio of 14.49, while VRTX has a forward P/E of 28.07, indicating GILD may be undervalued compared to VRTX [5] - GILD's PEG ratio is 0.74, suggesting a favorable valuation when considering expected earnings growth, whereas VRTX's PEG ratio is 1.20 [5] - GILD's P/B ratio is 7.38, compared to VRTX's P/B of 7.78, further supporting GILD's stronger valuation metrics [6] Analyst Outlook - GILD currently holds a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to VRTX, which has a Zacks Rank of 3 (Hold) [3][6] - The solid earnings outlook for GILD positions it as the superior value option in comparison to VRTX [6]

Core Viewpoint - Gilead Sciences, Inc. announced positive data from its phase I study of lenacapavir, a once-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP) [1][2][4] Group 1: Study Results - The phase I study evaluated the pharmacokinetics, safety, and tolerability of two intramuscular single-dose 5000mg lenacapavir formulations, involving 40 healthy adults aged 18 to 55 [3][6] - The study demonstrated that both formulations achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy observed in late-stage studies [4][5] - The most commonly reported adverse event was injection site pain, which was alleviated by pretreatment with an ice pack, with medication-emergent adverse events being mostly mild to moderate [6] Group 2: Market Position and Future Plans - Gilead's shares have increased by 56.8% over the past year, contrasting with an 8.6% decline in the industry [2] - The company plans to initiate a phase III study for once-yearly lenacapavir in the second half of 2025 [4] - Lenacapavir is already approved in multiple countries for treating adults with multi-drug resistant HIV, and its potential approval for PrEP could further solidify Gilead's position in the HIV market [8][10] Group 3: Competitive Landscape - Gilead's Biktarvy remains the top prescribed regimen for both treatment-naïve and switch patients, maintaining a strong market share [8][10] - The approval of lenacapavir would enhance Gilead's competitive edge, as it requires administration only twice yearly compared to daily oral medications [10] - The HIV treatment landscape is becoming increasingly competitive, with GSK reporting a 13% growth in HIV sales in 2024, driven by demand for long-acting injectable medicines [12][13]